Table 2.
Effect of IL-12 and IFN-γ Treatment in HKLMP-primed BALB/c Mice*
| Treatment of HKLMP- primed mice | Liver parasite burden | % Inhibition of Replication‡ | ||||
|---|---|---|---|---|---|---|
| Day +21 | +28 | |||||
| LDU | ||||||
| Day +1 to +7 | ||||||
| None | (see below) | 2,561 ± 170 | − | |||
| Saline | NT§ | 2,682 ± 101 | 0 | |||
| IL-12 | NT | 546 ± 93+ | 79 | |||
| IFN-γ | NT | 1,893 ± 107 | 26 | |||
| Day +21 to +28 | ||||||
| None | 1,761 ± 132 | 2,561 ± 170 | − | |||
| Saline | − | 2,351 ± 97 | 8 | |||
| IL-12 | − | 767 ± 63++ | 70 | |||
| IFN-γ | − | 1,267 ± 139+ | 51 | |||
*
BALB/c mice were pretreated for 4 wk with HKLMP, challenged with L. donovani, and received either no treatment or were subsequently treated for 7 d with pump-administered saline, IL-12 (1 μg/d), or IFN-γ (2 × 105 U/d). 7-d pumps were implanted either 4 h after challenge or not until 3 wk later (day +21). All treated mice were killed on day +28. Results are from two (IL-12) to three experiments (IFN-γ), and indicate mean ± SEM values for 6–10 mice per group.
‡
Compared to day +28 LDU in untreated control mice.
§
NT, not tested +P <.05 versus untreated controls on day +28. ++P <.05 versus untreated controls on both +21 and +28.